NCT04620239 2026-02-04
UCM301
Steba Biotech S.A.
Phase 3 Recruiting
Clinical Trials
8 trialsNCT03315754 2024-12-20
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
Steba Biotech S.A.
Phase 2 Active not recruiting
NCT04225299 2020-11-13
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
Phase 3 Withdrawn
NCT01310894 2019-07-11
PCM301
Steba Biotech S.A.
Phase 3 Completed
NCT00707356 2016-04-19
Study of WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed
NCT00975039 2016-04-18
Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
Steba Biotech S.A.
Phase 2 Terminated
NCT00974662 2015-04-28
Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer
Steba Biotech S.A.
Phase 2 Terminated
NCT00975429 2015-04-28
Study Using WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed